Rogers R L, Javed T A, Ross R E, Virella G, Stuart R K, Frei-Lahr D
Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston 29425, USA.
Am J Hematol. 1998 Apr;57(4):326-30. doi: 10.1002/(sici)1096-8652(199804)57:4<326::aid-ajh10>3.0.co;2-6.
A patient with multiple myeloma was noted to have an IgA deficiency during investigation of a possible transfusion reaction due to IgA deficiency and anti-IgA. Because of the patient's age, otherwise good health, and early stage of disease, he was enrolled in a research treatment protocol that involved an allogeneic bone marrow transplant (BMT). The BMT successfully put the patient in complete remission from his multiple myeloma and corrected his IgA deficiency. Class-specific IgG anti-IgA antibody that had been identified prior to BMT was no longer detectable in his plasma. Anaphylactic transfusion reactions were successfully avoided by using a combination of IgA-deficient and washed blood components including the marrow graft, and IgA-reduced intravenous immunoglobulin.
一名多发性骨髓瘤患者在因IgA缺乏和抗IgA导致的可能输血反应调查中被发现存在IgA缺乏。由于患者年龄、其他方面健康状况良好且疾病处于早期阶段,他被纳入了一项涉及异基因骨髓移植(BMT)的研究治疗方案。骨髓移植成功使患者的多发性骨髓瘤完全缓解,并纠正了他的IgA缺乏。骨髓移植前检测到的特异性IgG抗IgA抗体在其血浆中不再可检测到。通过使用包括骨髓移植物在内的IgA缺乏和洗涤后的血液成分以及IgA含量降低的静脉注射免疫球蛋白的组合,成功避免了过敏输血反应。